Evaluation of phentermine and topiramate versus phentermine/topiramate extended‐release in obese adults

Objective A 28‐week, randomized, controlled trial compared the combination of phentermine and topiramate extended‐release (PHEN/TPM ER) with its components as monotherapies and with placebo in obese adults. Design and Methods Subjects were randomized to placebo, phentermine 7.5 mg, phentermine 15 mg, topiramate ER 46 mg, topiramate ER 92 mg, PHEN/TPM ER 7.5/46 mg, or PHEN/TPM ER 15/92 mg. All subjects received lifestyle intervention counseling. Primary endpoints were percent weight loss (WL) and achievement of ≥5% WL. Results At week 28, PHEN/TPM ER 7.5/46 (−8.5%) and 15/92 (−9.2%) achieved greater percentage WL versus placebo (−1.7%; P